Download PDF
Nuklearmedizin 2013; 52(04): 121-129
DOI: 10.3413/Nukmed-0541-12-11
Original article
Schattauer GmbH

Distant metastatic lesions in patients with differentiated thyroid carcinoma

Clinical implications of radioiodine and FDG uptakeFernmetastasen bei Patienten mit differenziertem SchilddrüsenkarzinomKlinische Bedeutung der Radioiod- und FDG-Aufnahme
C. M. Hong
1   Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
,
B.-C. Ahn
1   Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
,
S. Y. Jeong
1   Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
,
S.-W. Lee
1   Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
,
J. Lee
1   Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
› Author Affiliations
Further Information

Publication History

received: 15 November 2012

accepted in revised form: 27 May 2013

Publication Date:
30 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Aim: Many investigators have reported an inverse relationship between iodine and glucose utilization of differentiated thyroid carcinoma (DTC) according to its degree of differentiation; however, not every DTC is compatible with this phenomenon. This study was conducted to evaluate the clinical implication of iodine and glucose uptake at distant metastatic lesions in DTC patients. Patients, methods: 64 DTC patients (women 47; mean age 49.9 ± 16.4 years) with distant metastasis who underwent post 131I treatment whole-body scan (RxWBS) and FDG PET/CT were included in the study. Radioiodine (RAI) and FDG uptake of metastatic lesions were evaluated. TSH stimulated serum thyroglobulin (s-Tg) were obtained. Results: 53 of 64 patients (82.8%) were RAI(+) group, and 37 patients (57.8%) were FDG(+) group. Patients in the RAI(–) group showed a higher rate of FDG uptake than RAI(+) group (100.0% vs. 49.1%, p = 0.002). Patients in the FDG(–) group showed a higher rate of RAI uptake than FDG(+) group (100.0% vs. 70.3%, p = 0.002). Patients with s-Tg < 100 ng/ml were frequently observed in the FDG(–)/RAI(+) group and the FDG(+)/ RAI(–) group (p = 0.023). And patients with s-Tg ≥ 500 ng/ml were more frequently observed in the FDG(+)/RAI(+) group, compared with the FDG(+)/RAI(–) group (p = 0.036). Reduced disease-specific survival (DSS) was observed in patients with RAI(–) (p = 0.003), FDG(+) (p = 0.006), SUVmax > 3.6 (p<0.001), and s-Tg > 75.8 ng/ml (p = 0.009). In multivariate analysis, only a SUVmax > 3.6 was significantly predictive of DSS (p = 0.006). Conclusion: An inverse relationship between RAI and FDG uptake, flip-flop phenomenon, was observed in patients with metastatic lesions of DTC. Reduced disease-specific survival was observed in patients with FDG(+), RAI(–) in metastatic lesions, or high s-Tg value.

Zusammenfassung

Ziel: Über den umgekehrten Zusammenhang zwischen Iod- und Glukoseverwertung des differenzierten Schilddrüsenkarzinoms (DTC) entsprechend dem Differenzierungsgrad wurde oft berichtet. Doch dieses Phänomen trifft nicht auf jedes DTC zu. Diese Studie wurde durchgeführt, um bei DTC-Patienten die klinischen Folgen der Iod- und Glukoseaufnahme in Fernmetastasen zu untersuchen. Patienten, Methoden: An der Studie nahmen 64 DTC-Patienten (47 Frauen; mittleres Alter 49,9 ± 16,4 Jahre) mit Fernmetastasen teil, bei denen je eine Ganzkörper-Szintigraphie (RxWBS) und FDG-PET/ CT-Untersuchung nach 131I-Behandlung vorgenommen wurde. Die Radioiod (RAI)- und FDG-Aufnahme der Fernmetastasen wurden untersucht und Thyroglobulin im Serum unter TSH-Stimulation (s-Tg) bestimmt. Ergebnisse: 53 von 64 Patienten (82,8%) wurden der RAI(+)-Gruppe, 37 Patienten (57,8%) der FDG(+)-Gruppe zugeordnet. Patienten der RAI(–)-Gruppe wiesen eine höhere Aufnahmerate von FDG auf als die RAI(+)-Gruppe (100,0% gegenüber 49,1%, p = 0,002). Patienten in der FDG(–)- Gruppe wiesen eine höhere Aufnahmerate von RAI auf als die FDG(+)-Gruppe (100,0% gegenüber 70,3%, p = 0,002). Patienten mit s-Tg < 100 ng/ ml waren häufig in der FDG(–)/RAI(+)-Gruppe und FDG(+)/RAI(–)-Gruppe anzutreffen (p = 0,023). Patienten mit s-Tg ≥ 500 ng/ ml waren häufiger in der FDG(+)/RAI(+)-Gruppe als in der FDG(+)/ RAI(–)-Gruppe anzutreffen (p = 0,036). Bei Patienten mit RAI(–) (p = 0,003), FDG(+) (p = 0,006), SUVmax > 3,6 (p<0,001) und s-Tg > 75,8 ng/ ml (p = 0,009) wurde ein niedrigeres krankheitsspezifisches Überleben (DSS) beobachtet. Bei der multivariaten Analyse war nur eine SUVmax > 3,6 signifikant prädiktiv für das DSS (p = 0,006). Schlussfolgerung: Bei Patienten mit DTC-Metastasen wurde ein umgekehrter Zusammenhang zwischen RAIund FDG-Aufnahme (Flip-Flop-Phänomen) beobachtet. Bei Patienten mit FDG(+) und RAI(–) in Metastasen oder hohem s-Tg-Wert wurde ein niedrigeres krankheitsspezifisches Überleben festgestellt.

Keywords

Flip-flop phenomenon - FDG - iodine - differentiated thyroid cancer - survival

Schlüsselwörter

Flip-Flop-Phänomen - FDG - Iod - differenziertes Schilddrüsenkarzinom - Überleben
 

  • References

  • 1 Ahn BC. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics 2012; 2: 392-402.
    CrossrefPubMedGoogle Scholar
  • 2 Ahn BC, Lee SW, Lee J. Multistage high-dose I-131 treatment for a nonthyroidectomized patient with metastatic differentiated thyroid cancer. Clin Nucl Med 2011; 36: e224-e227.
    CrossrefPubMedGoogle Scholar
  • 3 Arturi F, Russo D, Schlumberger M. et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998; 83: 2493-2496.
    PubMedGoogle Scholar
  • 4 Bachelot A, Cailleux AF, Klain M. et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002; 12: 707-711.
    CrossrefPubMedGoogle Scholar
  • 5 Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009; 115: 3801-3807.
    CrossrefPubMedGoogle Scholar
  • 6 Cooper DS, Doherty GM, Haugen BR. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
    CrossrefPubMedGoogle Scholar
  • 7 Durante C, Haddy N, Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-2899.
    CrossrefPubMedGoogle Scholar
  • 8 Edge SB, Byrd DR, Compton CC. et al. AJCC Cancer Staging Manual.. 7th ed. Springer; New York: 2010
  • 9 Feine U, Lietzenmayer R, Hanke JP. et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-1472.
    PubMedGoogle Scholar
  • 10 Feng F, Wang H, Fu H. et al. Dedifferentiation of differentiated thyroid carcinoma cell line FTC-133 is enhanced by 131I pretreatment. Nucl Med Biol 2011; 38: 1053-1058.
    CrossrefPubMedGoogle Scholar
  • 11 Grabellus F, Nagarajah J, Bockisch A. et al. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012; 37: 121-127.
    CrossrefPubMedGoogle Scholar
  • 12 Hong CM, Ahn BC, Park JY. et al. Prognostic implications of microscopic involvement of surgical resection margin in patients with differentiated papillary thyroid cancer after high-dose radioactive iodine ablation. Ann Nucl Med 2012; 26: 311-318.
    CrossrefPubMedGoogle Scholar
  • 13 Huang IC, Chou FF, Liu RT. et al. Long-term outcomes of distant metastasis from differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2012; 76: 439-447.
    CrossrefPubMedGoogle Scholar
  • 14 Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998; 83: 2638-2648.
    CrossrefPubMedGoogle Scholar
  • 15 Khan N, Oriuchi N, Higuchi T. et al. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003; 76: 690-695.
    CrossrefPubMedGoogle Scholar
  • 16 Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002; 37: 169-174.
    CrossrefPubMedGoogle Scholar
  • 17 Mihailovic J, Stefanovic L, Malesevic M, Markoski B. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases. Thyroid 2009; 19: 227-232.
    CrossrefPubMedGoogle Scholar
  • 18 Oh JR, Byun BH, Hong SP. et al. Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2011; 38: 1459-1468.
    CrossrefPubMedGoogle Scholar
  • 19 Paeng J, Kang K, Park D. et al. Alternative medical treatment for radioiodine-refractory thyroid cancers. Nucl Med and Mol Imaging 2011; 45: 241-247.
    Google Scholar
  • 20 Riemann B, Uhrhan K, Dietlein M. et al. Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study. Nuklearmedizin 2013; 52: 1-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Robbins RJ, Wan Q, Grewal RK. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91: 498-505.
    CrossrefPubMedGoogle Scholar
  • 22 Roelants V, Nayer PD, Bouckaert A, Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 1997; 24: 722-727.
    PubMedGoogle Scholar
  • 23 Rosenbaum-Krumme SJ, Gorges R, Bockisch A, Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012; 39: 1373-1380.
    CrossrefPubMedGoogle Scholar
  • 24 Rosenbaum-Krumme SJ, Wieduwilt M, Nagarajah J. et al. Estimation of tumour mass in patients with differentiated thyroid carcinoma using serum thyroglobulin. Nuklearmedizin 2012; 51: 217-222.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Sampson E, Brierley JD, Le LW. et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007; 110: 1451-1456.
    CrossrefPubMedGoogle Scholar
  • 26 Shoup M, Stojadinovic A, Nissan A. et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003; 197: 191-197.
    CrossrefPubMedGoogle Scholar
  • 27 Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll of Radiol) 2010; 22: 395-404.
    CrossrefPubMedGoogle Scholar
  • 28 Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48: 932-945.
    CrossrefPubMedGoogle Scholar
  • 29 Wang W, Larson SM, Fazzari M. et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: 1107-1113.
    PubMedGoogle Scholar
  • 30 Wang W, Larson SM, Tuttle RM. et al. Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001; 11: 1169-1175.
    CrossrefPubMedGoogle Scholar
  • 31 Wong KK, Zarzhevsky N, Cahill JM. et al. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol 2009; 82: 860-876.
    CrossrefPubMedGoogle Scholar
  • 32 Zettinig G, Leitha T, Niederle B. et al. FDG positron emission tomographic, radioiodine, and MIBI imaging in a patient with poorly differentiated insular thyroid carcinoma. Clin Nucl Med 2001; 26: 599-601.
    CrossrefPubMedGoogle Scholar
  • 33 Ziessman HA, O’Malley JP, Thrall JH. Nuclear Medicine: The Requisites in Radiology.. 3rd ed. Philadelphia: Elsevier Mosby; 2006
  • 34 Zimmermann-Belsing T, Rasmussen AK, Feldt-Rasmussen U. Lack of thyroglobulin synthesis as an indicator of early random dedifferentiation of the Fischer rat thyroid cell line FRTL-5. Scand J Clin Lab Invest 1998; 58: 529-535.
    CrossrefPubMedGoogle Scholar